2007 FDA approvals

As has been pointed out on many occasions, 2007 was a lean year for new drug approvals. The FDA approved only 17 new molecular entities (NMEs) last year--19 if you include two new biologics (Soliris and Mircera) OK'd by CDER. NMEs are perhaps the most important form of approval because they have never been approved by the FDA in any other form. The dearth of NMEs has industry watchers thinking that pharma's pipeline may be drying up, or that the FDA is getting stricter with its approval process--or both.

Many candidates missed the final goal last year, but here's a look at the drugs that made it through the rigorous drug discovery process and earned FDA approval in 2007.

1. Vyvanse - New River Pharmaceuticals

2. Tekturna - Novartis

3. Tykerb - GlaxoSmithKline

4. Soliris - Alexion

5. Altabax - GlaxoSmithKline

6. Neupro - Schwarz BioSciences

7. Torisel - Wyeth

8. Letairis - Gilead Sciences

9. Selzentry - Pfizer

10. Ammonia N 13 - Feinstein

11. Somatuline Depot - Biomeasure

12. Doribax - Johnson & Johnson

13. Isentress - Merck

14. Ixempra - Bristol-Myers Squibb

15. Tasigna - Novartis

16. Mircera - Roche

17. Kuvan - BioMarin

18. Bystolic - Forest Laboratories and Mylan

19. Voluven - Fresenius Kabi

 

Click here for special reports on biotech layoffs, R&D pipelines, industry trends, predictions and more.

Read more on

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.